TABLE III.
AXIN2 In Silico Analysis
| Panel 1. Re-analysis of prostate samples from Taylor et al [27]. Clinical criteria for sample selection: radical prostatectomy, no neoadjuvant or adjuvant hormones. Search filter: AXIN2, prostate cancer, recurrence versus no recurrence, mRNA, gene rank top 10%ile | ||||
|---|---|---|---|---|
| [27] | Recurrence (N = 32) | Expression mean (range): −0.057 (−0.165, 0.051) | P-value 0.003 (t-test) | |
| No recurrence (N = 102) | Expression mean (range): 0.102 (0.053, 0.150) | |||
| Recurrence (N = 32) | Expression median (range): −0.129 (−0.706, 0.572) | P-value 0.008 (Wilcoxon) | ||
| No recurrence (N = 102) | Expression median (range): 0.101 (−0.583, 0.651) | |||
| Panel 2. Search filter: AXIN2, prostate cancer, pathology subtype, mRNA, gene rank top 10%ile | ||||
| Ref | Description (N) | Fold Change | Gene Rank | P-value |
| [27] | Gleason Score 9 (7) versus 8 (8)versus 7 (74) versus 6 (41) | −0.235 | 590 | 0.007 |
| Lymph node+ (6) versus Lymph node— (102) | −1.223 | 1160 | 0.01 | |
| [28] | Stage 4 (3) versus Stage 3 (23) versus Stage 2 (20) | −0.266 | 1838 | 0.037 |
| [29] | Gleason Score 9 (5) versus 8 (10) versus 7 (18) versus 6 (23) | −0.0101 | 3160 | 0.231 |
| Lymph node+ (5) versus Lymph node— (48) | −1.048 | 5127 | 0.395 | |
| [30] | Gleason Score 7 (7) versus 6 (3) | −1.947 | 2211 | 0.086 |
| [31] | Gleason Score 9 (15) versus 6 (12) | −1.095 | 4237 | 0.034 |
| Panel 3. Search filter: AXIN2, prostate cancer, metastasis versus primary, mRNA, gene rank top 10%ile | ||||
| Ref | Description (N) | Fold Change | Gene Rank | P-value |
| [32] | Metastasis (35) versus Primary (59) | −3.288 | 1465 | 2.6 × 10−9 |
| [29] | Metastasis (7) versus Primary (57) | −1.758 | 961 | 0.005 |
| [27] | Metastasis (19) versus Primary (131) | −1.212 | 1776 | 0.007 |
| [33] | Metastasis (6) versus Primary (7) | −3.448 | 68 | 2.3 × 10−7 |
| [34] | Metastasis (17) versus Primary (10) | 1.622 | 1060 | 2.8 × 10−8 |
| [31] | Metastasis (5) versus Primary (27) | −1.091 | 2364 | 0.07 |
| [35] | Metastasis (12) versus Primary (23) | −1.217 | 3601 | 0.133 |
Association of low AXIN2 with clinical outcome defined as recurrence versus no recurrence (Panel 1, re-analysis of raw data), pathologic features (Panel 2, Gleason score and lymph node involvement), and disease dissemination (Panel 3, metastasis versus primary tumor).